Efficacy and safety of radium-223 in routine clinical practice
https://doi.org/10.17650/1726-9776-2020-16-4-129-135
Abstract
Several treatment options are currently available for patients with metastatic castration-resistant prostate cancer in routine clinical practice. However, clear standards of sequential use of registered drugs have not yet been developed. Affecting bone metastases, radium-223 is one of therapeutic options for patients with castration-resistant prostate cancer and bone metastases, which was included in foreign and Russian guidelines for prostate cancer management. This article analyzes the results of treatment with radium-223 in patients with metastatic castration-resistant prostate cancer in foreign non-interventional clinical trials conducted in routine clinical practice. These trials confirmed high efficacy and safety of radium-223 demonstrated earlier in the ALSYMPCA trial. Some protocols ensured better overall survival rates and lower incidence of symptomatic skeletal events and adverse events than those in the registration study.
About the Authors
V. B. Matveev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: not
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: not
A. S. Markova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: not
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: not
References
1. Bubendor F.L., Schopfer A., Wagner U. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31(5):578-83. DOI: 10.1053/hp.2000.6698.
2. Pezaro C., Omlin A., Lorente D. et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 2014;65(2):270-3. DOI: 10.1016/j.eururo.2013.10.055.
3. Mottet N., Cornford P., van der Bergh R.C.N. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer (2020). Available at: https://uroweb.org/wp-content/uploads/EAU-EANM-ESTRO-ESUR-SIOG-Guidelines-on-Prostate-Cancer-2020v4.pdf.
4. Schaeffer E., Srinivas S., Antonarakis E. et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) -prostate cancer (version 3.2020) (2020). Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
5. Clinical Guidelines of the Russian Association of Oncologists for the treatment of patients with prostate cancer 2020. Available at: https://oncology-association.ru/wp-content/uploads/2020/09/rak_predstatelnoj_zhelezy.pdf. (In Russ.).
6. Parker C., Nilsson S., Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23. DOI: 10.1056/NEJMoa1213755.
7. Hoskin P., Sartor O., O’Sullivan J.M. et al. Efficacy and safety of radium-223 dichloride in patients with castrationresistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, doubleblind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15:1397-406. DOI: 10.1016/S1470-2045(14)70474-7.
8. Saad F., Carles J., Gillessen S. et al. Radium-223 and concomitant therapies in patients with metastatic castrationresistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016;17(9):1306-16. DOI: 10.1016/S1470-2045(16)30173-5.
9. Higano C.S., Saad F., Sartor A.O. et al. Clinical outcomes and patient (pt) profiles in REASSURE: an observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2020;38(6_suppl):32. DOI: 10.1200/JCO.2020.38.6_suppl.32.
10. Clinical Guidelines “Prostate cancer” of the Russian Ministry of Health 2020. Available at: http://cr.rosminzdrav.ru/#!/recomend/99. (In Russ.).
11. Higano C.S., Harshman L.C., Dizdarevic S. et al. Safety and overall survival (OS) in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy. J Clin Oncol 2020;38 (15_suppl):5542.
12. Dizdarevic S., Petersen M.D., Essler M. et al. Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in nonintervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. Eur J Nucl Med Mol Imag 2019;46:1102-10. DOI: 10.1007/s00259-019-4261-y.
13. Smith M., Parker C., Saad F. et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(3):408-19. DOI: 10.1016/S1470-2045(18)30860-X.
14. European Medicines Agency (EMA). EMA restricts use of prostate cancer medicine Xofigo. 2018. Available at: https://www.ema.europa.eu/en/news/ema-restricts-use-prostate-cancer-medicine-xofigo.
15. Shore N.D., Tutrone R.F., Mariados N.F. et al. eRADicAte: a prospective evaluation combining radium-223 dichloride and abiraterone acetate plus prednisone in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 2018;16(2):149-54. DOI: 10.1016/j.clgc.2017.10.022.
16. Shore N., Higano C.S., George D.J. et al. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2020;23:680-8. DOI: 10.1038/s41391-020-0236-0.
17. Poeppel T., Eschmann S., Werner A. et al. 828 P Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): an interim review of a prospective, noninterventional study (PARABO). Annal Oncol 2020;29(Suppl 8):VIII289-90. DOI: 10.1093/annonc/mdy284.037.
18. Sternberg C.N., Saad F., Graff J.N. et al. A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Ann Oncol 2020;31(2):257-65. DOI: 10.1016/j.annonc.2019.10.025.
19. Sartor O., Vogelzang N.J., Sweeney C. et al. Radium-223 safety, efficacy, and concurrent use with abiraterone or enzalutamide: first U.S. experience from an expanded access program. Oncologist 2018;23(2):193-202. DOI: 10.1634/theoncologist.2017-0413.
20. https://clinicaltrials.gov/ct2/show/NCT02194842.
21. https://clinicaltrials.gov/ct2/show/NCT03574571.
Review
For citations:
Matveev V.B., Markova A.S. Efficacy and safety of radium-223 in routine clinical practice. Cancer Urology. 2020;16(4):129-135. (In Russ.) https://doi.org/10.17650/1726-9776-2020-16-4-129-135
Views:
575
Email this article 